Scientific Publications by FDA Staff
FEBS Open Bio 2012 May 24;2:113-8
Effects of carbon monoxide (CO) delivery by a CO donor or hemoglobin on vascular hypoxia inducible factor 1a and mitochondrial respiration.
Reiter CE, Alayash AI
We examined carbon monoxide (CO) delivery by carbon monoxide-releasing molecule 2 (CORM-2) or hemoglobin (Hb) on cellular oxygen sensing and mitochondrial respiration in bovine aortic endothelial cells (BAECs). CORM-2 reduced hypoxia-inducible factor-1a (HIF-1a) and endothelin-1 (ET-1) expression in normoxic and hypoxic cells, but while Hb alone significantly reduced HIF-1a stabilization in hypoxic cells, CO delivered by Hb (Hb-CO) had no effect on HIF-1a stabilization. CO dose-dependently increased basal oxygen consumption and reduced overall mitochondrial respiratory capacity. Hb-CO increased basal oxygen consumption but did not alter respiratory capacity. Together, CO reduced ET-1, and, at low doses, had no effect on endothelial mitochondria oxygen consumption. CO ligation to Hb may be developed further as non-vasoactive oxygen therapeutic without compromising mitochondrial function.
|Category: Journal Article|
|PubMed ID: #23650589||DOI: 10.1016/j.fob.2012.05.003|
|PubMed Central ID: #PMC3642129|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2012-03-31||Entry Last Modified: 2013-05-14|